LONDON—Three of Europe's largest drug makers saw their earnings fall in the third quarter, underscoring the challenge facing pharmaceutical companies as drugs lose patent protection and competition increases from cheaper substitutes.

European pharmaceutical firms, along with their global counterparts, are seeing the worst effects of the so-called "patent cliff" this quarter, where patents for drugs expire in major territories but aren't replaced rapidly enough to replace lost revenues. The losses are amplified by austerity...